Selegiline and oxidative stress in HIV-associated cognitive impairment.
about
Role of neuroimaging in HIV-associated neurocognitive disordersSoluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected womenNeural correlates of working memory training in HIV patients: study protocol for a randomized controlled trial.Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.Genetic variation and HIV-associated neurologic disease.Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cellsHIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities.Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease.Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway.HIV-associated neurocognitive disorders: perspective on management strategiesAdjuvant therapies for HIV-associated neurocognitive disorders.Spatial Memory Performance Associated with Measures of Immune Function in Elderly Female Rhesus MacaquesNovel mechanisms of central nervous system damage in HIV infection.Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals.Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes.Regional cortical thinning associated with detectable levels of HIV DNA.Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action.Current understanding of HIV-associated neurocognitive disorders pathogenesis.Smoothened Agonist Reduces Human Immunodeficiency Virus Type-1-Induced Blood-Brain Barrier Breakdown in Humanized Mice.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.More than two HANDs to tango.Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.HIV-associated neurological disorders: a guide to pharmacotherapy.Interventions for Neurocognitive Dysfunction.Sonic Hedgehog mimetic prevents leukocyte infiltration into the CNS during acute HIV infection.Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q26852705-048D4E41-A802-4CA2-8DAB-E5B61FA61808Q28729739-D0A56767-4786-4E26-9D6F-E019F5026004Q30391907-EDE323C8-9B30-4E40-9CF6-5258AB335B4AQ30452291-2109C58D-5CC0-4013-8679-364DB050CE8EQ33819189-7D276E24-C594-4C73-9320-FB7700970F57Q33873538-27716BB1-0D51-42B4-9193-EA8CD31F7BACQ34037622-C862BA0F-D663-4A59-8FDD-16A7E9C33A62Q34141266-424F0E05-E1E1-4B14-A7FD-596965C2EF3CQ34377373-2FBF02EC-B23E-40E4-938F-9BE4288C1036Q34652590-38CF801F-D66E-43D9-9EF1-3888C0BA5582Q34692081-F6BB2049-3D7E-4DB8-BB86-21B9EC81C531Q34989558-9CFDD839-94E5-454E-BAC7-A5781B5A4C68Q35557261-92AF1281-0312-4E78-9E8E-9E504BEB99E3Q35588145-019751C7-3C7B-40D8-A484-4FAEEA99365BQ36028974-8E9ED509-9803-428E-9BD1-F3F93738E716Q36142331-46A3A1F5-DCE4-44B5-ADE6-3BE3327FDF77Q36712281-CAD46CED-D44D-41D8-B265-4F6C30D63FD0Q36932005-7355F944-5556-44FD-B8C7-04B8FA69F1B5Q36950205-5A27D656-C461-49DF-A362-ADAD9CA0785AQ37122279-403C241F-EF9C-4BC7-B251-04F2CA33CBA2Q37467989-3F455680-D020-4ACD-A5C8-3ED6A13BF69FQ37900614-BFF71E63-3EFE-4B12-BF0C-E99C441B1BE4Q37971469-AF6F2792-3460-4470-BFEC-57D1A7A74B1CQ38767396-024F99DC-585E-4476-9BE7-C835ED7B4A49Q40065929-A735294A-6AA8-4013-BCB0-D29F2A0C33BCQ47590480-015CFC88-65E1-4050-931A-D438AB8C6C29Q57180790-4358459F-2034-497F-9D1F-FF38B67444ED
P2860
Selegiline and oxidative stress in HIV-associated cognitive impairment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Selegiline and oxidative stress in HIV-associated cognitive impairment.
@en
Selegiline and oxidative stress in HIV-associated cognitive impairment.
@nl
type
label
Selegiline and oxidative stress in HIV-associated cognitive impairment.
@en
Selegiline and oxidative stress in HIV-associated cognitive impairment.
@nl
prefLabel
Selegiline and oxidative stress in HIV-associated cognitive impairment.
@en
Selegiline and oxidative stress in HIV-associated cognitive impairment.
@nl
P2093
P2860
P1433
P1476
Selegiline and oxidative stress in HIV-associated cognitive impairment.
@en
P2093
ACTG 5114 Team
C Anderson
C T Yiannoutsos
D B Clifford
G Schifitto
P2860
P304
P356
10.1212/WNL.0B013E3181C51A48
P407
P577
2009-11-04T00:00:00Z